MaxCyte Webinars

1. Enhancing Non-Viral CAR T Manufacturing With Electroporation And Microbubble T Cell Isolation 10/22/2025

   Unlock superior non-viral CAR T manufacturing outcomes by combining gentle microbubble T cell isolation with advanced electroporation. See how this approach boosts cell viability and transfection efficiency.

2. Navigating Challenging Cell Engineering Workflows With A Scalable, Proven Electroporation Platform 9/1/2025

   Discover how a scalable, non-viral electroporation platform delivers complex payloads into hard-to-transfect cells, ensuring high efficiency and viability from discovery to clinical-scale production.

3. High Efficiency Cell Engineering Seminar 8/13/2025

   Discover the challenges of cell engineering, and learn how to maintain high cell viability while scaling up with difficult-to-transfect cell types like primary and stem cells.

4. How To Mitigate Gene Editing Program Risk Through Comprehensive Off-Target Safety Profiling And Characterization 8/13/2025

   A critical challenge for therapeutic programs using CRISPR is managing the risk of off-target effects. Learn how to strengthen the safety of your therapeutic programs with comprehensive assessments.

5. Mitigate Clinical Risk In Cell Therapy Development With A GMP Compliant Process 4/21/2025

   Help shape the future of medicine by building better, safer cell therapies. See how expertise in scalable, GMP-compliant cell engineering can effectively mitigate clinical development risks.

6. High Efficiency Cell Engineering From Concept To Clinic 4/21/2025

   Discover how highly efficient and scalable methods for engineering cells are accelerating the development and delivery of next-generation cell-based treatments for patients.

7. Emerging Manufacturing Technologies For Cell Therapies | Audience Q&A 4/15/2025

   Cell & Gene Live’s Audience Q&A always draws valuable questions in real time from our audience. Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio provide detailed responses to audience questions that addressed the importance of vein-to-vein time for non-cancer indications, such as autoimmune diseases.

8. The Impact Of Cell Therapy Manufacturing On Patient Access And Experience 4/15/2025

   During this segment of Cell & Gene Live, expert panelists, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio share why improvements in cell therapy manufacturing directly impact the patient experience.

9. Implementing Emerging Manufacturing Technologies For Cell Therapies 4/15/2025

   In this segment of Cell & Gene Live, Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio emphasize the importance of focusing on solving the problem at hand when adopting new technologies.

10. Emerging Technologies In Cell Therapy Manufacturing: Embracing Automation, Robotics, And AI 4/15/2025

    In this segment of our Cell & Gene Live, expert panelists Rohit Ingale, Head of Manufacturing & MSAT, Arcellx and David O’Donnell, Vice President, Head of Manufacturing, Vor Bio define innovation as benefiting patients and emphasize automation and robotics as central to the cause.